GlassScriptPhysician profile
Michele O Fallon
NPI 1902877251
$5,828.64
in general payments reported to CMS, 2019-2025
48 companies · $880 in 2025
The $880 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $655 · 2021: $530 · 2022: $661 · 2023: $783 · 2024: $844 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.59 |
| Education | $123.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $731.40 | 2019-2025 | Benlysta, Nucala, Arexvy |
| Abbvie INC. | $696.28 | 2019-2025 | |
| Amgen INC. | $503.49 | 2019-2025 | Tavneos, Enbrel, Repatha |
| Pfizer INC. | $435.33 | 2019-2025 | |
| Lilly USA, LLC | $301.65 | 2019-2025 | Taltz, Zepbound, Mounjaro |
| Astellas Pharma US INC | $288.86 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Biotech, INC. | $281.14 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $273.18 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $230.62 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $201.67 | 2019-2025 | Airsupra, Saphnelo, Breztri |
| Merck Sharp & Dohme LLC | $126.67 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.87 | 2019-2024 | Xifaxan, Trulance |
| Alexion Pharmaceuticals, INC. | $116.49 | 2021-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.14 | 2019-2023 | |
| Mallinckrodt Enterprises LLC | $85.70 | 2019 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele O Fallon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.